Abstract Body

Background:

Publicly funded, centrally distributed HIV PrEP with emtricitabine-tenofovir has been available in British Columbia (BC) since January 2018. We evaluated PrEP persistence and estimated medication utilization using longitudinal prescription data from BC’s PrEP program.

Methods:

BC PrEP participants with ≥1 dispensed PrEP prescription (Rx) between 1-Jan-2018 to 30-Jun-2022 and ≥1 year follow-up opportunity were included. Demographics and PrEP Rx data were described, and PrEP persistence characterized by 1, 2 or ≥3 Rx. Multinomial logistic regression was used to obtain the univariate odds ratio (OR) to compare persistence in ≥3 vs. 1 Rx for variables of interest. For those with ≥3 Rx, PrEP utilization was estimated by calculating proportion of days covered (PDC), and stratified by prescribed daily vs. non-daily use.

Results:

Overall, 9375 participants were included [median (Q1-Q3) age 32 (27-41) years; 96.9% cis-men, 1.3% trans-women, 0.9% cis-women, 0.5% trans-men; 54.3% reside in Vancouver]. 98.4%, 0.7%, and 0.2% qualified with men who have sex with men (MSM)-, heterosexual-, and injection drug use-based risk criteria, respectively. 80% (n=7520) of participants persisted with PrEP ≥3 Rx, while 9% and 11% received only 1 and 2 Rx’s, respectively. A significant difference in the odds of PrEP persisting ≥3 vs. 1 Rx was observed in several subgroups: age category 18-28 years (Ref. >48 years) (OR 0.7 [95% CI, 0.5-0.8], p=0.0002); gender cis-women (Ref. cis-male) (OR 0.2 [0.1-0.3], p<0.0001); trans-women (OR 0.3 [0.2-0.4], p<0.0001); trans-men (OR 0.4 [0.2-0.8], p=0.0077); non-MSM HIV acquisition risk group (Ref. MSM) (OR 0.5 [0.3-0.9], p=0.0323); no prior PrEP use (Ref. prior use) (OR 0.6 [0.5-0.7], p<0.0001); residence outside Vancouver (Ref. Vancouver) (OR 0.6 [0.6-0.7], p<0.0001). Of 7520 participants with ≥3 Rx, 93% were prescribed daily PrEP, with median (Q1-Q3) PDC 0.83 (0.6-0.96), median PDC follow-up time of 30 (15-50) months and median Rx count of 8 (5-14). For non-daily PrEP (7%), median PDC was 0.49 (0.3-0.67), median PDC follow-up time was 42 (21-54) months, and median Rx count was 7 (5-11). 77% of daily users had median overall PDC >0.57 and 53.6% had PDC >0.8.

Conclusions:

In a population-level program, 80% of participants demonstrated PrEP persistence ≥3 Rx. Persistence was decreased amongst younger, non-cis-men participants, and those residing outside the urban centre. Overall estimates of PrEP utilization suggest non-daily or interrupted use in many prescribed daily PrEP.